Wellgistics Launches XRP Payments, Seeks $7.5M in Equity Offering

TL;DR

**WGRX is making a high-risk, high-reward bet on blockchain payments and aggressive M&A, but the lack of a minimum offering makes this a speculative play.**

AI Summary

Wellgistics Health, Inc. (WGRX) is offering up to 5,357,142 shares of Common Stock and accompanying Warrants, with an assumed combined public offering price of $1.40 per share and warrant, based on the Nasdaq closing price on September 17, 2025. The company is also offering Pre-Funded Warrants for purchasers exceeding 4.99% beneficial ownership, exercisable at $0.0001 per share, with an assumed combined price of $1.3999. WGRX, founded in 2022, operates as a holding company for pharmaceutical and healthcare services, conducting business through subsidiaries like Wood Sage LLC, Wellgistics, LLC, Wellgistics Tech & Hub, LLC, and Wellgistics Pharmacy, LLC. Key acquisitions include Wood Sage LLC on June 16, 2024, and Wellgistics, LLC on August 30, 2024. In April 2025, WGRX entered an agreement to acquire Peek Healthcare Technologies, Inc., a digital prescription platform. A significant recent development is the August 2025 launch of a blockchain-based payment integration leveraging the XRP Ledger (XRPL) to facilitate secure, low-cost, real-time payments with pharmacy customers, allowing payments in XRP. The offering will terminate on October 31, 2025, and H.C. Wainwright & Co. is acting as the exclusive placement agent, receiving a 7.0% cash fee and Placement Agent Warrants.

Why It Matters

This S-1/A filing signals Wellgistics Health's aggressive expansion strategy through both acquisitions and innovative technology adoption, particularly with its blockchain-based payment system using XRP. For investors, the offering of up to 5,357,142 shares and warrants at $1.40 per unit could dilute existing shareholders, but also provides capital for growth and integration of its 'micro health ecosystem.' Employees and customers could benefit from enhanced service offerings and potentially more efficient payment processes. The move into blockchain payments with XRP could disrupt traditional healthcare payment systems, putting pressure on competitors to innovate or risk falling behind in a rapidly evolving market.

Risk Assessment

Risk Level: high — The offering explicitly states, "Because there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering, we may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us." This creates substantial uncertainty regarding the capital available for business goals. Additionally, the company is an "emerging growth company" and a "smaller reporting company," indicating inherent risks associated with early-stage, less regulated entities.

Analyst Insight

Investors should approach WGRX with extreme caution, recognizing the high-risk nature due to the lack of a minimum offering amount and the speculative blockchain integration. Consider a small, speculative position only if you have a high-risk tolerance and believe in the long-term potential of their integrated healthcare ecosystem and XRP payment strategy, but be prepared for significant volatility and potential capital loss.

Key Numbers

• $1.40 — Assumed combined public offering price (Per share of Common Stock and accompanying Warrant)
• 5,357,142 — Maximum shares of Common Stock offered (Number of shares offered in the public offering)
• 5,357,142 — Maximum Warrants offered (Number of Warrants accompanying Common Stock or Pre-Funded Warrants)
• $0.0001 — Pre-Funded Warrant exercise price (Exercise price per share for Pre-Funded Warrants)
• 7.0% — Placement Agent cash fee (Percentage of gross proceeds paid to H.C. Wainwright & Co.)
• $100,000 — Placement Agent expense reimbursement cap (Maximum legal and out-of-pocket expenses reimbursed to Placement Agent)
• $15,950 — Placement Agent clearing expenses (Amount reimbursed to Placement Agent for clearing expenses)
• 7.0% — Placement Agent Warrants percentage (Percentage of shares/Pre-Funded Warrants sold, issued as Placement Agent Warrants)
• October 31, 2025 — Offering termination date (Date by which the offering will terminate unless earlier discretionarily terminated)
• $1.53 — Last reported sale price of Common Stock (On Nasdaq on September 11, 2025)

Key Players & Entities

• Wellgistics Health, Inc. (company) — Registrant and offering company
• H.C. Wainwright & Co., LLC (company) — Exclusive placement agent for the offering
• Brian Norton (person) — Agent for service and owner of Wellgistics, LLC
• Nasdaq Capital Market (regulator) — Exchange where WGRX Common Stock is traded
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing
• Wood Sage LLC (company) — Wholly owned subsidiary acquired by Wellgistics Health
• Wellgistics, LLC (company) — Wholly owned subsidiary acquired by Wellgistics Health, a pharmaceutical distributor
• Peek Healthcare Technologies, Inc. (company) — Company to be acquired by Wellgistics Health, a digital prescription platform
• XRP Ledger (XRPL) (company) — Blockchain technology leveraged for payment integration
• RxERP (company) — Partner for blockchain payment program implementation

FAQ

Risk Factors

• Dependence on Key Personnel [medium — operational]: The company's success is heavily reliant on its management team, particularly its ability to attract and retain qualified personnel. The loss of key individuals could significantly disrupt operations and hinder strategic execution.
• Healthcare Regulatory Compliance [high — regulatory]: As a healthcare and pharmaceutical services company, Wellgistics Health is subject to extensive and evolving federal, state, and local regulations. Non-compliance could lead to significant penalties, operational disruptions, and reputational damage.
• Competition in Pharmaceutical and Healthcare Services [medium — market]: The company operates in a highly competitive landscape with established players and emerging companies. Intense competition could impact pricing, market share, and profitability.
• Reliance on Future Financing [high — financial]: The company's business plan, including acquisitions and expansion, may require significant capital. There is no assurance that additional financing will be available on terms favorable to the company, or at all.
• Integration of Acquisitions [medium — operational]: The company has recently completed or is in the process of acquiring Wood Sage LLC, Wellgistics, LLC, and Peek Healthcare Technologies, Inc. The successful integration of these entities is critical, and failure to do so could disrupt operations and dilute potential synergies.
• Adoption of Blockchain Payment Technology [medium — market]: The company's launch of a blockchain-based payment integration using XRP Ledger is a novel approach. The success of this initiative depends on customer adoption, regulatory acceptance, and the stability of cryptocurrency markets.
• Potential Litigation and Legal Claims [low — legal]: As with many companies, Wellgistics Health may be subject to various legal proceedings and claims arising from its business operations. Adverse outcomes could result in significant financial liabilities.

Industry Context

Wellgistics Health operates within the dynamic pharmaceutical and healthcare services sector, characterized by rapid technological advancements and evolving regulatory landscapes. The industry faces increasing pressure for cost-efficiency and improved patient outcomes, driving innovation in areas like digital health platforms and payment solutions. Competition is fierce, with established players and agile startups vying for market share.

Regulatory Implications

The company's operations are subject to stringent healthcare regulations (e.g., HIPAA, FDA requirements) and financial regulations related to securities offerings. Compliance is paramount, as violations can lead to severe penalties, operational disruptions, and reputational damage. The novel use of blockchain and cryptocurrency for payments introduces potential new regulatory scrutiny.

What Investors Should Do

1. Evaluate the strategic rationale and integration risks of recent acquisitions (Wood Sage, Wellgistics, Peek Healthcare).
2. Assess the potential and risks associated with the blockchain payment integration using XRPL.
3. Analyze the company's capital requirements and future financing plans.
4. Scrutinize the terms of the offering, including the combined price of $1.40 per share and warrant, and the placement agent's fees and warrants.

Key Dates

• 2022-01-01: Company Founded — Marks the inception of Wellgistics Health, Inc. as a holding company.
• 2024-06-16: Acquisition of Wood Sage LLC — Significant step in expanding the company's operational footprint and service offerings.
• 2024-08-30: Acquisition of Wellgistics, LLC — Further consolidation and expansion of the company's core business segments.
• 2025-04-01: Agreement to Acquire Peek Healthcare Technologies, Inc. — Strategic move to integrate a digital prescription platform, enhancing technological capabilities.
• 2025-08-01: Launch of Blockchain-Based Payment Integration (XRPL) — Introduction of innovative payment solutions leveraging cryptocurrency, aiming for efficiency and cost reduction.
• 2025-10-31: Offering Termination Date — The deadline for the current public offering of shares and warrants.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC for securities offerings. It allows companies to update or correct information previously filed. (This document is the primary source of detailed information about Wellgistics Health's offering and business.)

Pre-Funded Warrants

Warrants that allow an investor to purchase shares at a nominal price, typically used to avoid triggering beneficial ownership thresholds (like 4.99%) in public offerings. (These are offered to specific purchasers to facilitate their investment while complying with ownership limits.)

Beneficial Ownership

The actual power to direct or the power to direct the vote and/or disposition of securities. Ownership thresholds often trigger disclosure requirements or limitations. (The 4.99% threshold is critical for determining who receives Pre-Funded Warrants.)

Placement Agent

A financial institution that assists a company in selling securities to investors, typically in private placements or registered direct offerings. (H.C. Wainwright & Co. is acting as the exclusive agent for this offering.)

XRP Ledger (XRPL)

A decentralized, public blockchain ledger that facilitates fast, low-cost, and reliable digital asset transactions, often associated with the cryptocurrency XRP. (This is the technology underpinning Wellgistics Health's new payment integration.)

Holding Company

A company whose primary business is holding a controlling interest in the securities of other companies. (Wellgistics Health operates as a holding company for its various pharmaceutical and healthcare service subsidiaries.)

Year-Over-Year Comparison

This S-1/A filing represents a significant update from any prior filings, primarily detailing the current public offering. Key developments include the recent acquisitions of Wood Sage LLC and Wellgistics, LLC, and the agreement to acquire Peek Healthcare Technologies, Inc. A notable strategic shift is the launch of a blockchain-based payment system leveraging XRP Ledger. These actions indicate a proactive approach to growth and innovation, though they also introduce new integration and market adoption risks not present in earlier stages.

Key Financial Figures

• $0.0001 — 2 shares of our Common Stock, par value $0.0001 per share (the “ Common Stock &rd
• $1 — purchase one share of Common Stock, is $1.40, which is equal to the last reported
• $0.125 — hare under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of common stock underly
• $1.53 — ck on Nasdaq on September 11, 2025, was $1.53 per share. There is no established publ
• $100,000 — t-of-pocket expenses in an amount up to $100,000, and for its clearing expenses in the a
• $15,950 — its clearing expenses in the amount of $15,950. In addition, we have agreed to issue t
• $0.55 — XRP traded within a range of less than $0.55 to above $3.60 per token, of which pric
• $3.60 — hin a range of less than $0.55 to above $3.60 per token, of which price volatility is

Filing Documents

• forms-1a.htm (S-1/A) — 2052KB
• ex4-1.htm (EX-4.1) — 129KB
• ex4-2.htm (EX-4.2) — 124KB
• ex4-3.htm (EX-4.3) — 142KB
• ex5-1.htm (EX-5.1) — 25KB
• ex10-21.htm (EX-10.21) — 251KB
• ex23-1.htm (EX-23.1) — 5KB
• ex107.htm (EX-FILING FEES) — 41KB
• ex5-1_001.jpg (GRAPHIC) — 8KB
• formdrs_001.jpg (GRAPHIC) — 16KB
• forms-1_002.jpg (GRAPHIC) — 152KB
• forms-1a_003.jpg (GRAPHIC) — 407KB
• 0001493152-25-014355.txt ( ) — 3731KB
• ex107_htm.xml (XML) — 16KB

USE OF PROCEEDS

USE OF PROCEEDS 11 CAPITALIZATION 12

DILUTION

DILUTION 13 INDUSTRY AND MARKET DATA 14

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 35 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION 41 MANAGEMENT 47 Director Compensation 51

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 51 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 52 PLAN OF DISTRIBUTION 55 LEGAL MATTERS 58 EXPERTS 58 INFORMATION INCORPORATED BY REFERENCE 59 WHERE YOU CAN FIND MORE INFORMATION 59 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS As used in this prospectus, unless the context otherwise requires, references to “ Wellgistics Health ,” the “ Company ,” “ we ,” “ us ,” “ our ” and similar terms refer to Wellgistics Health, Inc., a Delaware corporation, and our consolidated subsidiaries. References to shares of “ Common Stock ” refer to shares of our common stock, par value $0.0001 per share. We are offering to sell, and seeking offers to buy, shares of our Common Stock only in jurisdictions where such offers and sales are permitted. The distribution of this prospectus and the offering of our Common Stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our Common Stock and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. You should rely only on the information contained in this prospectus, any related free-writing prospectus, and any prospectus to which we have referred you. Neither we nor the Placement Agent has authorized any other person to provide you with information different from that contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or

View Full Filing

View this S-1/A filing on SEC EDGAR